Author： Gouldthorpe Oliver Catto-Smith Anthony G. Alex George Simpson Di
Publisher： MDPI
E-ISSN： 1424-8247|6|10|1322-1334
ISSN： 1424-8247
Source： Pharmaceuticals, Vol.6, Iss.10, 2013-10, pp. : 1322-1334
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Secondary loss of response (LoR) often precludes further use of infliximab in children with Crohn’s disease. Immunomodulators may reduce the incidence of LoR but their combination with infliximab presents safety concerns. We aimed to determine the long-term durability of infliximab response in paediatric Crohn’s, effect of immunomodulators on LoR, and secondarily the effect of infliximab on growth. We retrospectively audited patients on maintenance infliximab at a single centre. Data included height and weight, Paediatric Crohn’s Disease Activity Index (PCDAI), and immunomodulator use. 71 children (32% female, mean age 14.4 years) had been commenced on maintenance infliximab before July 2011. 89% had been on immunomodulators concurrently with infliximab. LoR occurred in 20 (28%), with a median time to LoR of 4.31 years. LoR was significantly increased in children who did not enter remission (PCDAI ≤ 10) after induction (
Related content
By Conca Paolo Cafaro Giovanni De Renzo Amalia Coppola Antonio Cimino Ernesto Tarantino Giovanni
International Journal of Molecular Sciences, Vol. 16, Iss. 6, 2015-06 ,pp. :
Access to resources
Recommend
By Lv Qing-Kang Liu Ju-Xiong Li Su-Nan Gao Ying-Jie Lv Yan Xu Zi-Peng Huang Bing-Xu Xu Shi-Yao Yang Dong-Xue Zeng Ya-Long Liu Dian-Feng Wang Wei
International Journal of Molecular Sciences, Vol. 16, Iss. 11, 2015-11 ,pp. :
By Wang Dong-Mei Yang Ya-Jun Zhang Li Zhang Xu Guan Fei-Fei Zhang Lian-Feng
International Journal of Molecular Sciences, Vol. 14, Iss. 3, 2013-03 ,pp. :